Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 SERUM LEVELS
ERBB2 SERUM LEVELS
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/973
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/416
Rating
3
Evidence Type
Prognostic
Disease
Breast Cancer
Evidence Direction
Supports
Evidence Level
B
Clinical Significance
Poor Outcome
Pubmed
26811533
Drugs